Navigation Links
Meningococcal-B Vaccine Greatly Reduces The Risk of The Disease

A new study has shown the children and teenagers who had been immunised against epidemic meningococcal B disease are five times less likely to be infected// than those who haven't been vaccinated.

Reports have shown that the biggest mass immunisation campaign that had taken place among the young New Zealanders has resulted in a five-fold reduction in the risk of acquiring Meningococcal B disease. The officials from the Ministry of health have stated that according to the initial results of the study conducted by the Victoria University of Wellington has showed that the children who were not immunised were almost five times more likely to suffer the disease. Stating that this disease has affected nearly 6,000 people since the epidemic began in 1981, they said that this disease has killed 239 people in a 25-year epidemic that has hit the country.

It has been reported that 1-in-5 of the survivors have been left with some degree of disability, that includes hearing loss, brain damage, amputation or scarring. Dr Jane O'Hallahan, the director of the immunisation programme has said that if the current trends continue, then substantial progress will been made towards ending the epidemic by the end of the year, which means it could be ended technically several years before its natural end.

Meningococcal disease is a bacterial infection, which causes severe illnesses including meningitis that is an infection of membranes covering the brain, and septicaemia a serious blood infection. Officials at the ministry have explained hat though anyone is vulnerable to the disease, the biggest risk group would be teenagers and children under 20 yrs of age, and more than half of those in that group are below 5 yrs.


'"/>




Page: 1

Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... 05, 2016 , ... BSI and Brenntag Canada have been appointed by Chr. ... of their natural fruits and beverage colorants effective November 1, 2016. ... our Life Sciences product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing ...
(Date:12/5/2016)... , ... December 05, 2016 ... ... Great Point Partners ("GPP") portfolio company, today announced it has acquired the ... TCS was previously a subsidiary of Chiltern International and focuses on ...
(Date:12/5/2016)... ... ... The new knee compression sleeves come as a pair which will provide ... lifting and any sport that requires knee compression or protection from the demands ... higher quality knee sleeve performance. Firstly it is made out of premium 7mm thick ...
(Date:12/5/2016)... OH (PRWEB) , ... December 05, 2016 , ... ... engineering solution called the CardioQuick Patch® significantly improves the reproducibility and accuracy of ... in various healthcare settings. , Over the last 60 years, studies have ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty Awards ... , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings together ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response ... and tolerability profile of ropeginterferon alfa-2b versus HU ... ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization ... present this data to the FDA as it seeks approval ...
(Date:12/4/2016)... SAN DIEGO , Dec. 3, 2016 Johnson ... filed on behalf of purchasers of Zimmer Biomet Holdings, Inc. ... September 7, 2016 through October 31, 2016 (the "Class Period"). ... It designs, manufactures, and markets orthopaedic reconstructive products, such as ... ...
(Date:12/4/2016)... 3, 2016   Pairnomix, LLC, a genetic research ... recognized by the White House, today announced that findings from ... identification of candidate therapies for a patient with epileptic encephalopathy ... were presented at the 70 th Annual Meeting of ... TX , December 2-6, 2016.  Pairnomix, unique ...
Breaking Medicine Technology: